AI in Pharma 2026: Where It Is Actually Working

Discovery and research: the most mature use of AI in pharma

Discovery is where AI has gone furthest, and the reason is structural rather than scientific. Preclinical research is not a GxP activity. A model that proposes a candidate molecule, predicts a binding affinity, or ranks a target library does not need a validated computerised system behind it, because nothing it produces goes directly into a regulatory submission or a patient. It produces a hypothesis, and the hypothesis is tested in a wet lab. The lab experiment is the control.

That freedom has produced real capability. Structure prediction is now a routine tool rather than a research novelty. Generative chemistry platforms are producing candidate series that medicinal chemists take seriously. Target identification using multi-omics and literature-scale evidence synthesis is embedded in the workflow at most large discovery organisations and a growing share of biotechnology companies.

The honest caveat: none of this has yet demonstrably compressed the overall timeline from target to approval. Several AI-discovered molecules have entered clinical trials; the attrition pattern so far looks broadly similar to conventionally discovered compounds. The gain is in the number of hypotheses a team can generate and triage per unit of time, not in a higher probability that a given candidate survives Phase II. Treat vendor claims about end-to-end timeline compression with scepticism until there is a body of approvals to point at.

Clinical development and documentation: production for drafting, pilot for anything decisional

Clinical documentation is the first regulated function where AI has genuinely reached production, and it got there by doing something narrow well. Safety narrative generation from structured case data, patient narrative assembly for a clinical study report, protocol section drafting from a synopsis, and literature summarisation for a clinical evaluation report are all tasks with a bounded input, a well-defined output format, and a qualified human who reads every word before it goes anywhere. That combination is validatable.

The organisations getting real value here share one implementation detail: the output is traceable. Every generated sentence carries a pointer back to the source record — the case form field, the listing row, the published paper — so a medical writer reviewing the draft can check a claim in seconds rather than reconstructing where it came from. Where that traceability is missing, review takes longer than writing from scratch and the pilot dies quietly. This is the whole premise behind TraceDraft, and it is also why CROs adopting these tools tend to do it document type by document type rather than all at once.

Still pilot-stage: anything that touches a clinical decision. Protocol design optimisation, adaptive trial recommendation engines, AI-driven site selection that materially changes enrolment strategy, and automated medical coding without review. These are not blocked by technology. They are blocked because nobody has yet built an assurance case that satisfies a sponsor's own quality organisation, let alone an inspector.

Regulatory operations: strong on assembly, weak on judgment

Regulatory affairs is quietly one of the better AI success stories in pharmaceuticals, and almost nobody markets it that way. Document assembly for a submission dossier, cross-checking a module against a health authority's structural requirements, mapping content between regional formats, and identifying inconsistencies across thousands of pages of a common technical document are all tasks where the input is structured, the rules are explicit, and the output is checkable against a specification.

Response drafting for health authority questions is further along than most people assume. A model with access to the submission corpus and the company's prior responses can produce a first draft that a regulatory lead edits rather than composes. The time saving is real and measurable, because the alternative is a person searching across a dossier for the relevant evidence.

What has not worked: regulatory strategy. Deciding which indication to pursue, how to frame a benefit-risk argument, or whether to challenge a health authority position is judgment work involving precedent, relationship, and commercial context that is not in the training data and often not written down anywhere. Companies that piloted AI for strategic regulatory input generally stopped, not because the output was wrong in an obvious way, but because it was confidently plausible in ways that were hard to check.

Manufacturing and process control: the widest gap between capability and deployment

Process analytical technology, multivariate batch monitoring, soft sensors, and predictive maintenance on manufacturing equipment are technically mature. The statistical methods behind most of them predate the current AI wave by twenty years. Yet the share of commercial GMP manufacturing lines running model-driven control in a validated state is small.

The reason is that a model influencing a batch decision is part of the control strategy, and the control strategy is in the filing. Changing it means a regulatory variation, comparability work, and a quality organisation willing to defend the change. A model that adapts after that filing — retrained on new batch data, drifting in behaviour — creates a control strategy that no longer matches what was approved. That is a serious problem, and it is why most manufacturing AI runs in an advisory lane: it flags, recommends, and alerts, but the batch release decision, the deviation call, and the parameter change stay with a person.

Advisory-lane deployment is not a failure. Predictive maintenance that prevents an unplanned line stop, or an early-warning model that flags a drifting parameter three hours before it breaches a limit, delivers value without touching the filed control strategy at all. The organisations doing well here deliberately chose the advisory lane rather than backing into it.

Quality and validation: from slowest adopter to one of the fastest

Quality was the last function anyone expected to adopt AI, and over the past two years it has become one of the more active. The shift happened because the work is unusually well suited to it. A validation package is a structured artefact: requirements, risk assessments, test cases, traceability, execution evidence. Generating a test script from a requirement is a bounded task with a verifiable output — you can read the script and check whether it tests the requirement. That is a far easier assurance problem than a model that recommends a clinical strategy.

In production today across a meaningful number of organisations: test case generation from requirements, traceability matrix maintenance, GAMP 5 classification proposals with a human confirming or overriding, deviation triage and similar-case retrieval, and periodic review scheduling driven by risk and change history. real GxP AI use cases in pharma walks through each of these with worked examples, and our guide to GxP test automation covers the test-generation case specifically.

What stays human: approval. Every one of these patterns terminates in a qualified person who signs. Under EU GMP Annex 22, that is not a design preference — an adaptive or generative model may not be the decision-maker on a GMP-critical question. why human-in-the-loop can't be a footnote explains why teams that treat human review as a checkbox rather than an architectural constraint tend to discover the problem during an inspection rather than during design. GxP Copilot was built with that constraint in the data model rather than in the SOP, which is a meaningfully different thing.

Pharmacovigilance: high volume, high scrutiny, real production use

Pharmacovigilance has the clearest economic case for automation in the whole industry. Case volumes grow year over year, the intake work is repetitive, and the regulatory clock is unforgiving. Case intake triage, duplicate detection across a safety database, MedDRA coding suggestions, literature screening, and seriousness and expectedness pre-assessment are all in production at large safety organisations and increasingly at mid-size ones.

The operating pattern is consistent: the model narrows and prepares, a safety physician or trained case processor decides. Duplicate detection is a good illustration — a model that surfaces twelve probable duplicates for review is useful and safe; a model that auto-merges them is neither, because a wrongly merged case is an under-reported case.

Signal detection is the harder frontier. Disproportionality analysis has been algorithmic for years, but moving from statistical signal to causality assessment involves clinical judgment that regulators expect a named qualified person to own. Expect AI to keep shrinking the noise around signal review rather than replacing the review itself.

Why so many pharma AI pilots never reach production

The industry-wide pattern is not a technology failure. In most stalled programmes the model worked adequately in the pilot and the team could see the value. What was missing was the assurance case: the documented, defensible answer to how you know this system does what you claim, how you will know if it stops doing it, and what happens when it produces something wrong.

Concretely, pilots stall for a short list of reasons that recur across companies:

• No evaluation set. The team judged output quality by impression rather than against a held-out set of cases with known-correct answers. Without that, there is no way to gate a release or detect a regression after a model update.
• The pilot scope was not the production scope. A demo on clean, curated data does not tell you how the system behaves on the messy historical records that make up most of the real corpus.
• No owner in quality. A pilot sponsored entirely by IT or a digital function has nobody who can validate it, and it reaches the validation conversation after the architecture is already fixed.
• The model was placed where a human decision belonged. Once a quality reviewer sees that the design makes the model the decider on a GMP-critical question, the programme is finished — correctly so.
• No fallback. Nobody defined what the process does on the day the model is unavailable or its output is rejected, which makes the system a single point of failure in a regulated workflow.

The organisations that get to production build the assurance case first and the pilot second. That ordering feels slower and is consistently faster. GxP AI vs. manual validation sets out what actually changes operationally once a team clears that bar, and the ROI of AI-first validation covers how the economics look when it works.

What to expect through 2026

Two things are likely. First, the regulated functions will keep closing the gap on the unregulated ones, because the assurance question is now well understood rather than novel — Annex 22 and the FDA's credibility-framework thinking have given teams something concrete to build against instead of a vacuum. Second, the marketing language will keep running ahead of deployment, particularly around autonomous agents in GMP contexts. When you evaluate a claim, ask what decision the system makes without a person, and what evidence exists that it makes it correctly. Most claims resolve quickly under that question.

If you are choosing where to put the next increment of effort, the pattern across functions is consistent: bounded task, structured input, checkable output, human approver. Everything in production today fits that shape. Almost nothing outside it does. book a demo if you want a direct read on where a specific use case in your organisation sits against that line.